UPDATE: The **International NUT Carcinoma Diagnosis and Treatment Center** officially opened its doors at **Boao International Hospital** in **Boao, China**, on **January 29, 2026**. This urgent development comes as a beacon of hope for patients battling **NUT carcinoma**, a rare and aggressive cancer notorious for its diagnostic challenges and limited treatment options.
The center is a collaborative effort between **Boao International Hospital** and **Chongqing University Three Gorges Hospital**, aiming to transform the landscape of NUT carcinoma care. Powered by a groundbreaking oral BET inhibitor, **NHWD-870**, developed by **Zhejiang Wenda Pharma Technology Co., Ltd.**, the center is poised to make a significant impact. Clinical trials reveal an **objective response rate of 33.3%** and a **disease control rate of 73.33%**, with a promising median overall survival of **9.3 months** for patients treated with this innovative drug.
Professor **YIN Mingzhu**, a leading figure at the center, stated,
“Our mission is to light a definitive beacon of hope. We are here to ensure every patient has access to advanced, life-extending care.”
This commitment underscores the center’s role as a critical hub for clinical advancements and patient support.
Strategically positioned within the **Boao Hope Pilot Zone of International Medical Tourism**, the center benefits from unique policy advantages that facilitate the expedited introduction of both international medical products and domestic innovations like NHWD-870. This zone has already paved the way for over **540 innovative therapies**, making it a vital gateway for medical advancements and international collaboration.
In addition to treating patients, the center will also spearhead a new research and innovation platform, establishing itself as a global hub for cutting-edge trials. This initiative builds on the solid foundation laid by **Chongqing University Three Gorges Hospital**, which has previously treated over **200 patients** and was instrumental in crafting China’s first expert consensus on NUT carcinoma.
The launch of the International NUT Carcinoma Center marks a significant milestone in rare disease care, aiming to change the narrative for patients suffering from this challenging condition. With ongoing clinical trials and a strong commitment to patient access, the center is set to redefine treatment standards and offer renewed hope to those affected by NUT carcinoma.
As this story develops, the medical community and patients alike are watching closely to see how these advancements will impact treatment options moving forward. For more information, visit the **International NUT Carcinoma Registry** at http://resource.yin-lab.com/NUT/.
Stay tuned for further updates on this groundbreaking initiative that holds the promise of transforming lives.
